Abstracts Archive - Page 2098 of 2425 - ACR Meeting Abstracts

Abstract Number: 2294 • 2013 ACR/ARHP Annual Meeting
The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic
Maria Dahl Mjaavatten¹, Anne Julsrud Haugen², Halvor Nygaard³, Olav Bjørneboe⁴, Patrik Stolt⁵, Cathrine Thunem⁶ and Tore Kristian Kvien^1,7, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ³Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ⁵Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, ⁶Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ⁷Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: In the ACR/EULAR criteria remission can be defined in two ways, either by fulfilment of 4 Boolean criteria or by a Simplified Disease Activity…
Abstract Number: 2295 • 2013 ACR/ARHP Annual Meeting
Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up
Tuulikki Sokka¹, Sigita Stropuviene², Hannu Kautiainen³, Tuomas Rannio⁴ and Jolanta Dadoniene², ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Vilnius Univ, Vilnius, Lithuania, ³Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁴Jyvaskyla Central Hospital, Jyväskylä, Finland
Background/Purpose: Life span of patients with rheumatoid arthritis (RA) is reduced by 3-10 years compared to non-RA population. Only recent reports indicate improvements in survival…
Abstract Number: 2296 • 2013 ACR/ARHP Annual Meeting
Are SDAI50 and DAS28 Response Measures Comparable In Early Rheumatoid Arthritis Patients?
Mohammed Omair¹, Edward C. Keystone², Juan Xiong³, Gilles Boire⁴, Janet E. Pope⁵, J. Carter Thorne⁶, Carol A. Hitchon⁷, Boulos Haraoui⁸, Diane Tin⁹, Deborah Weber³, Vivian P. Bykerk² and Pooneh Akhavan², ¹Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵St Joseph Health Care, London, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: An essential element of treat to target strategy is adjusting therapy in the absence of achieving a target response by 12 wk. A DDAS28…
Abstract Number: 2297 • 2013 ACR/ARHP Annual Meeting
Evaluating Depression Questionnaires In German Rheumatoid Arthritis Patients – Preliminary Results From a Validation Study
Matthias Englbrecht¹, Rieke Alten², Martin Aringer³, Christoph G. Baerwald⁴, Harald Burkhardt⁵, Nancy Eby⁶, Gerhard Fliedner⁷, Bettina Gauger⁸, Ulf Henkemeier⁹, Michael Hofmann¹⁰, Stefan Kleinert¹¹, Christian Kneitz¹², Christoph Pohl¹³, Georg Schett¹, Marc Schmalzing¹⁴, Anne-Kathrin Tausche¹⁵, Hans Peter Tony¹⁶ and Joerg Wendler¹⁷, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ³Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁴Rheumatology, University Hospital, Leipzig, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ⁶Biostatistics, AMS-Advanced Medical Services, Mannheim, Germany, ⁷Praxis Osnabrück, Germany, Germany, Osnabrück, Germany, ⁸Roche Pharma AG, Grenzach, Germany, ⁹University Hospital Frankfurt, Frankfurt, Germany, ¹⁰Chugai Pharma, Frankfurt, Germany, ¹¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ¹²Internal Medicine II, Hospital Südstadt, Rostock, Germany, ¹³Rheumatology,Clinical Immunolo, Schlosspark Klinik, Berlin, Germany, ¹⁴Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ¹⁵Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹⁶Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ¹⁷Schwerpunktpraxis Rheumatologie, Erlangen, Germany
Background/Purpose: To date, only a few studies have discussed the prevalence of depression in RA patients in Germany and depression questionnaires have not been validated…
Abstract Number: 2298 • 2013 ACR/ARHP Annual Meeting
Upper-Half Serum IgA (20+ TU/ml) and IgM (10+ IU/ml) Levels Significantly Predicted The Long-Term (mean 12 yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹, Huaping Wang², Ned J. Goertzen³ and Marius C. Teodorescu⁴, ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL, ³University of Illinois College of Medicine at Peoria, Peoria, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL
Background/Purpose: Serum rheumatoid factor (RF) is a major predictor of the new onset of rheumatoid arthritis (RA). In very early arthritis patients, higher titers…
Abstract Number: 2299 • 2013 ACR/ARHP Annual Meeting
Disease Activity Scoring: Comparing Patient and Physician Global Assessment Of Disease Activity In Rhumatoid Arthritis Patients Starting a First Biologic Agent
Boulos Haraoui¹, Louis Bessette², Diane Sauvageau¹, Jean Pierre Pelletier³, Jean-Pierre Raynauld¹, Edith Villeneuve¹, Louis Coupal³ and Denis Choquette³, ¹Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: Visual analogue scales (VAS) are routinely used in daily clinical practice and are part of the different composite outcome measures such as the DAS,…
Abstract Number: 2300 • 2013 ACR/ARHP Annual Meeting
Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting
Gary Craig^1,2, Howard Kenney^1,2, Keith Knapp² and Sergio Schwartzman³, ¹Arthritis Northwest PLLC., Spokane, WA, ²T3 JointMan LLC., Spokane, WA, ³Rheumatology, Hosp for Special Surgery, New York, NY
Background/Purpose: The public database JointManTMwas launched January 2012 with a mission to provide a practical outcome tool to manage patients with RA in a clinical…
Abstract Number: 2301 • 2013 ACR/ARHP Annual Meeting
T Cell Proliferative Response To Type II Collagen In Patients With Rheumatoid Arthritis
Nida Saleem¹, Tahir Aziz Ahmed², Javaid Mahmood Malik³, Mushtaq Ahmed⁴ and Mukarram Bashir⁵, ¹IMMUNOLOGY, Armed Forces Institute Of Pathology, RAWALPINDI, Pakistan, ²Dept of Immunology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan, ³Rahmat Noor Clinic and Arthritis Research Centre, Rawalpindi, Pakistan, ⁴Medicine, Military Hospital Rawalpindi, rawalpindi, Pakistan, ⁵IMMUNOLOGY, Armed Forces Institute Of Pathology, rawalpindi, Pakistan
Background/Purpose: To compare the frequency of Collagen II reactive T cells in RA patients and healthy control and evaluating the relationship of Collagen II reactive…
Abstract Number: 2302 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis
Shunichi Shiozawa¹, Leendert A. Trouw² and Kazuko Shiozawa³, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³The Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
Background/Purpose: Serology represents a powerful tool for the identification and sub-classification of patients with rheumatoid arthritis (RA). IgM-rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies…
Abstract Number: 2303 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis
Ryosuke Hiwa¹, Koichiro Ohmura¹, Noriyuki Yamakawa¹, Moritoshi Furu², Chikashi Terao³, Ran Nakashima¹, Yoshitaka Imura⁴, Naoichiro Yukawa⁵, Hajime Yoshifuji¹, Motomu Hashimoto⁶, Hiromu Ito², Takao Fujii² and Tsuneyo Mimori^1,2, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ⁴Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Although anti-citrullinated peptide/protein antibody (ACPA) is a specific autoantibody for rheumatoid arthritis (RA), ~20% of RA are ACPA negative. It has been reported that…
Abstract Number: 2304 • 2013 ACR/ARHP Annual Meeting
Follow-Up Of Patients With Preclinical Rheumatoid Arthritis – Results Of a Telephone Survey
Pascal Klaus¹, Vivien Köhler¹, Hans Bastian¹, Tanja Braun¹, Eva Gremmelsbacher¹, Vera Höhne-Zimmer¹, Frank Buttgereit¹, Gerd Burmester¹ and Jacqueline Detert², ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany
Background/Purpose: Preclinical rheumatoid arthritis (pre-RA) describes a subset of patients with arthralgia (but no synovitis) where either anti-citrullinated peptide antibodies (ACPA) and/or rheumatoid factor (RF)…
Abstract Number: 2305 • 2013 ACR/ARHP Annual Meeting
Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients
Vanesa Hernández-Hernández¹, Ivan Ferraz-Amaro², Esmeralda Delgado-Frías¹, Sagrario Bustabad-Reyes¹ and Federico Diaz-Gonzalez³, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ³Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: It is generally assumed that rheumatoid arthritis (RA) patients tend to exercise less than what is currently recommended. However, there is little data on…
Abstract Number: 2306 • 2013 ACR/ARHP Annual Meeting
Comparative Study Of Patients With Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis Without Psoriasis
Abhijeet Danve¹, Neha Garg² and Atul A. Deodhar³, ¹Rheumatology, Oregon Health and Science University, Portland, OR, ²Internal Medicine, Division of arthritis and rheumatic diseases, Oregon Health and Sciences University, Portland, OR, ³Oregon Health and Science University, Portland, OR
Background/Purpose: Axial involvement in Psoriatic Arthritis (PsA) is reported to be between 40 -70%. Both, axial and peripheral arthritis in patients with PsA can cause…
Abstract Number: 2307 • 2013 ACR/ARHP Annual Meeting
Lifestyle Factors Were Seldom Discussed With Patients Visiting a Rheumatology Clinic
Ann B. I. Bremander^1,2 and Stefan Bergman^2,3, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund, Lund University, Lund, Sweden, ²Spenshult Research and Development Center, Halmstad, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: There is increasing evidence that lifestyle factors are of importance for outcome of rheumatic diseases, and lifestyle interventions should be a natural part of…
Abstract Number: 2308 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Flares: Inflammatory Or Avalanche?
Caroline A. Flurey¹, Marianne Morris², Jon Pollock¹, Rodney A. Hughes³, Pamela Richards⁴ and Sarah Hewlett⁵, ¹Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ²University of the West of England, Bristol, United Kingdom, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom, ⁴Academic Rheumatology Unit, University of Bristol, Bristol, United Kingdom, ⁵Academic Rheumatology, University of the West of England, Bristol, United Kingdom
Background/Purpose: Previous research has not addressed how RA patients' symptoms change daily. The aim of this study was to explore symptom patterns during daily life…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].